Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

International Paper to snap up DS Smith in £7.8bn deal

(Sharecast News) - International Paper has agreed to buy British rival DS Smith in a £7.8bn all-share deal, it was confirmed on Tuesday. In a joint statement, the US and UK companies said the combination would create "a truly global sustainable packaging solutions leader", with industry-leading positions in both Europe and North America.

Under the terms of the recommended offer, DS Smith shareholders will receive 0.1285 new International Paper shares for each DS Smith share they hold.

Shares in the blue chip have been valued at 415p - based on the closing price of 25 March, the day before DS Smith first announced the offer - giving it an enterprise value of around £7.8bn.

The deal dwarfs an earlier offer from fellow UK rival Mondi, which had agreed an all-share takeover worth around £6.2bn in March, shortly before International Paper launched its own approach.

Miles Roberts, chief executive of DS Smith, said: "In a dynamic sustainable packaging landscape, the combination will enhance our global proposition to customers, create opportunities for colleagues and drive value for shareholders."

Mark Sutton, chief executive of International Paper, said: "Combining with DS Smith is a logical next stop in International Paper's strategy to drive profitable growth by strengthening our global packaging business."

The Tennessee-based paper and pulp giant said it expected to achieve around $514m of pre-tax cash synergies on an annual basis after four years.

Once the tie-up is complete, DS Smith shareholders will own 33.7% and International Paper investors 66.3%. International Paper will also seek a secondary listing of its shares on the London Stock Exchange.

The deal is expected to close by the fourth quarter of this year.

Share this article

Related Sharecast Articles

Hikma boosts injectables business with Xellia assets acquisition
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.